EA021437B1 - Соединения, ингибирующие lrrk2 киназную активность - Google Patents

Соединения, ингибирующие lrrk2 киназную активность Download PDF

Info

Publication number
EA021437B1
EA021437B1 EA201270480A EA201270480A EA021437B1 EA 021437 B1 EA021437 B1 EA 021437B1 EA 201270480 A EA201270480 A EA 201270480A EA 201270480 A EA201270480 A EA 201270480A EA 021437 B1 EA021437 B1 EA 021437B1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxy
methyl
phenylmethyl
mmol
pyridinylbenzamide
Prior art date
Application number
EA201270480A
Other languages
English (en)
Russian (ru)
Other versions
EA201270480A1 (ru
Inventor
Пола Луиз Николс
Эндрю Джон Итертон
Пол Бамборо
Карамджит Сингх Джанду
Оливер Джеймс Филпс
Даниеле Андреотти
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201270480A1 publication Critical patent/EA201270480A1/ru
Publication of EA021437B1 publication Critical patent/EA021437B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EA201270480A 2009-09-29 2010-09-27 Соединения, ингибирующие lrrk2 киназную активность EA021437B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24655009P 2009-09-29 2009-09-29
CN2010001334 2010-09-02
PCT/CN2010/001501 WO2011038572A1 (en) 2009-09-29 2010-09-27 Novel compounds

Publications (2)

Publication Number Publication Date
EA201270480A1 EA201270480A1 (ru) 2013-08-30
EA021437B1 true EA021437B1 (ru) 2015-06-30

Family

ID=43825509

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270480A EA021437B1 (ru) 2009-09-29 2010-09-27 Соединения, ингибирующие lrrk2 киназную активность

Country Status (15)

Country Link
US (1) US8778939B2 (enExample)
EP (1) EP2483254B1 (enExample)
JP (1) JP5752691B2 (enExample)
KR (1) KR20120081609A (enExample)
AU (1) AU2010302842B2 (enExample)
BR (1) BR112012006859A2 (enExample)
CA (1) CA2775753A1 (enExample)
EA (1) EA021437B1 (enExample)
ES (1) ES2512727T3 (enExample)
IL (1) IL218674A (enExample)
IN (1) IN2012DN02763A (enExample)
MX (1) MX2012003778A (enExample)
SG (1) SG179120A1 (enExample)
WO (1) WO2011038572A1 (enExample)
ZA (1) ZA201201877B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2634716C2 (ru) * 2011-11-29 2017-11-03 Дженентек, Инк. Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
AR082827A1 (es) * 2010-09-02 2013-01-09 Glaxo Group Ltd Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson
CA3017869C (en) 2010-11-10 2021-07-27 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
ES2660996T3 (es) * 2011-05-03 2018-03-27 PRCL Research Inc. Compuestos para la inflamación y usos relacionados con el sistema inmunitario
CN103917525B (zh) * 2011-05-23 2016-08-17 依兰制药公司 Lrrk2激酶活性的抑制剂
US9096609B2 (en) * 2011-09-30 2015-08-04 Ipsen Pharma S.A.S. Macrocyclic LRRK2 kinase inhibitors
MX348920B (es) 2011-11-29 2017-07-04 Genentech Inc Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
KR102012057B1 (ko) 2011-11-29 2019-08-19 제넨테크, 인크. Lrrk2 조절제로서 아미노피리미딘 유도체
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
RU2650641C2 (ru) 2011-11-30 2018-04-16 Дженентек, Инк. Фтор-18 и углерод-11 меченые радиолиганды для томографии с позитронной эмиссией (рет), визуализирующей lrrk2
CA2878054C (en) 2012-06-29 2018-09-11 Pfizer Inc. Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
EP3539965B1 (en) * 2013-12-09 2021-01-20 Unichem Laboratories Limited An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
CN105940004B (zh) * 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN106604913A (zh) 2014-03-31 2017-04-26 纽约哥伦比亚大学理事会 组蛋白乙酰基转移酶激活剂及其用途
WO2015176010A1 (en) 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
TR201909606T4 (tr) 2014-07-31 2019-07-22 Basf Se Pi̇razollari hazirlamak i̇çi̇n i̇şlem
CN105348182B (zh) * 2014-08-24 2018-04-13 复旦大学 2‑烷氧基苯甲酰芳胺类化合物及其药物用途
CA2960777A1 (en) 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
BR112017023935B1 (pt) 2015-05-11 2020-07-07 Basf Se processo para a preparação de um composto
DK3294725T3 (da) * 2015-05-11 2021-07-26 Basf Se Fremgangsmåde til fremstilling af 4-aminopyridaziner
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
US20190297887A1 (en) 2016-07-12 2019-10-03 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
CN110446700A (zh) * 2017-01-25 2019-11-12 葛兰素史密斯克莱知识产权发展有限公司 化合物
JP6728503B2 (ja) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
KR101990739B1 (ko) 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101990738B1 (ko) 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
US20220396575A1 (en) 2019-08-30 2022-12-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
JP2025034990A (ja) * 2023-08-31 2025-03-13 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法、化合物、及び酸拡散制御剤
CN119432181B (zh) * 2024-11-28 2025-07-15 佛山市德堡建材有限公司 一种环保型聚合物水泥防水涂料及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008135A1 (de) * 1995-08-30 1997-03-06 Bayer Aktiengesellschaft Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel
US20060276496A1 (en) * 2005-03-17 2006-12-07 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-Cytokine Heterocyclic Compounds
WO2007030567A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
WO2007103839A2 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449691A (en) * 1991-12-31 1995-09-12 Sterling Winthrop Inc. 3,4-disubstituted anilines-immunomodulating agents
CA2288330C (en) 1997-05-07 2014-02-11 University Of Pittsburgh Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
CN1301154A (zh) 1998-03-26 2001-06-27 日本烟草产业株式会社 酰胺衍生物和nociceptin拮抗剂
ES2215893T3 (es) 2000-03-17 2004-10-16 Bristol-Myers Squibb Pharma Company Derivados de beta-aminoacidos como inhibidores de metaloproteasas de matriz y tnf-alfa.
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
DE10159453A1 (de) 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
CA2482341A1 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel methoxybenzamide compounds for use in mch receptor related disorders
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
MXPA05011536A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
WO2005073210A1 (ja) * 2004-01-28 2005-08-11 Kissei Pharmaceutical Co., Ltd. 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
US7671077B2 (en) 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
WO2010048559A2 (en) 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008135A1 (de) * 1995-08-30 1997-03-06 Bayer Aktiengesellschaft Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel
US20060276496A1 (en) * 2005-03-17 2006-12-07 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-Cytokine Heterocyclic Compounds
WO2007030567A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
WO2007103839A2 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2634716C2 (ru) * 2011-11-29 2017-11-03 Дженентек, Инк. Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)

Also Published As

Publication number Publication date
IN2012DN02763A (enExample) 2015-09-18
EP2483254A1 (en) 2012-08-08
US20120184553A1 (en) 2012-07-19
AU2010302842A1 (en) 2012-04-12
BR112012006859A2 (pt) 2019-09-24
EP2483254B1 (en) 2014-08-13
IL218674A (en) 2015-11-30
EP2483254A4 (en) 2013-02-27
MX2012003778A (es) 2012-06-01
WO2011038572A1 (en) 2011-04-07
SG179120A1 (en) 2012-05-30
ES2512727T3 (es) 2014-10-24
US8778939B2 (en) 2014-07-15
JP5752691B2 (ja) 2015-07-22
ZA201201877B (en) 2012-11-28
JP2013505969A (ja) 2013-02-21
CA2775753A1 (en) 2011-04-07
AU2010302842B2 (en) 2014-05-08
EA201270480A1 (ru) 2013-08-30
IL218674A0 (en) 2012-05-31
KR20120081609A (ko) 2012-07-19

Similar Documents

Publication Publication Date Title
EA021437B1 (ru) Соединения, ингибирующие lrrk2 киназную активность
RU2482112C2 (ru) Ингибиторы киназ, применимые для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
US20080269267A1 (en) Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
US10954232B2 (en) Pyrazole derivative as ALK5 inhibitor and uses thereof
EA019722B1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
HK1217482A1 (en) Enzyme modulators and therapies
TW200938535A (en) Modulators for amyloid beta
JP5587246B2 (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
US20230140808A1 (en) (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer
US10752609B2 (en) GSK-3 inhibitors
CN110753690B (zh) 吡啶衍生物
CN102596921B (zh) 新化合物
TW202417429A (zh) 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物
NZ749951B (en) Novel pyrazole derivative as alk5 inhibitor and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU